Welcome to our dedicated page for QuidelOrtho Corporation news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on QuidelOrtho Corporation stock.
QuidelOrtho Corporation (symbol: QDEL) is a prominent American manufacturer specializing in diagnostic healthcare products that are distributed globally. The company focuses on the development, manufacturing, and marketing of rapid diagnostic testing solutions, which are crucial for both clinicians and patients worldwide. QuidelOrtho’s product portfolio includes immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing comprehensive solutions that aid in critical medical decisions.
With a strong geographical presence in North America, EMEA (Europe, the Middle East, and Africa), China, and other countries, QuidelOrtho generates the majority of its revenue from North America. The corporation is committed to innovation and quality, continually striving to improve diagnostic accuracy and efficiency.
Recent achievements of QuidelOrtho Corporation include significant advancements in rapid diagnostic testing technologies that ensure faster and more accurate results. The company has also entered strategic partnerships and launched new products that enhance its market position and expand its global footprint.
For investors and stakeholders, QuidelOrtho’s solid financial performance and ongoing projects demonstrate its robust growth potential. The company’s latest updates, news releases, and financial reports reflect its dedication to driving progress in the healthcare diagnostics industry.
Latest News:
- SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation announces new strategic partnerships and product launches aiming to bolster its market presence.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced that it will report its financial results for the second quarter of 2024 on Wednesday, July 31, 2024, after the market close. The company will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results.
Interested parties can access the call through the 'Events & Presentations' section of QuidelOrtho's Investor Relations webpage. Presentation materials will be posted at the time of the call. Those unable to access the webcast can join via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) with Conference ID 533267. A replay of the call will be available on the company's website shortly after the event.
QuidelOrtho (Nasdaq: QDEL), a leader in in vitro diagnostic technologies, announced its management team's participation in the 44th Annual William Blair Growth Stock Conference. The event is scheduled for June 5, 2024, in Chicago, IL. The company's presentation will take place at 1:20 p.m. CT. Interested parties can access the live webcast and replay on QuidelOrtho's Investor Relations page.
QuidelOrtho (Nasdaq: QDEL) has launched a new state-of-the-art distribution center in Pedricktown, New Jersey, enhancing its U.S. distribution footprint. This strategic move aims to strengthen supply chain resilience and improve the customer experience. Partnering with a third-party logistics provider, QuidelOrtho aims to fulfill orders more efficiently. The company is also committed to sustainability, introducing greener, paper-based packaging that is recyclable. This initiative is expected to impact 15-20% of its domestic shipments over the coming months.
QuidelOrtho reported global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue. They are undergoing cost reduction initiatives to save approximately $100 million annually. The company suspended its 2024 financial guidance as they assess the business under a new President and CEO. Revenue for Q1 2024 was $711 million, with non-respiratory revenue flat at $574 million and respiratory revenue at $137 million, a 48% decrease due to lower COVID-19 revenue. The company appointed Brian J. Blaser as President and CEO effective May 6, 2024.
QuidelOrtho (Nasdaq: QDEL) appoints Brian J. Blaser as President and Chief Executive Officer, bringing over two decades of leadership experience in the In-Vitro Diagnostics Industry. The Board of Directors expands to eleven members, with Mr. Blaser joining on May 15, 2024. Known for his success in transformational strategies to drive revenue growth and profitability, Mr. Blaser's appointment is set to guide QuidelOrtho through its next phase of growth.
FAQ
What is the current stock price of QuidelOrtho Corporation (QDEL)?
What is the market cap of QuidelOrtho Corporation (QDEL)?
What does QuidelOrtho Corporation specialize in?
Where is QuidelOrtho Corporation headquartered?
What are the main products offered by QuidelOrtho?
How does QuidelOrtho support clinicians and patients?
What recent achievements has QuidelOrtho Corporation made?
What regions contribute most to QuidelOrtho's revenue?
What is the stock symbol for QuidelOrtho Corporation?
How can I stay updated with the latest news about QuidelOrtho?
Does QuidelOrtho engage in any partnerships?
What is the primary focus of QuidelOrtho's diagnostics?
